4928-43-2

Basic information

• Product Name: N2,N2-dimethylpyridine-2,5-diamine
• Synonyms: N,N-Dimethylpyridine-2,5-diamine;N,N-Dimethyl-2,5-pyridinediamine;(5-amino-2-pyridyl)-dimethyl-amine;N~2~,N~2~-dimethyl-2,5-pyridinediamine(SALTDATA: FREE);2-Dimethylamino-5-aminopyridine;3-Amino-6-(dimethylamino)pyridine;5-Amino-2-(dimethylamino)pyridine
• CAS NO: 4928-43-2
• Molecular Formula: C₇H₁₁N₃
• Molecular Weight: 137.19
• EINECS: 225-564-7
• Product Categories: pharmacetical
• Mol File: 4928-43-2.mol

Chemical Properties

• Boiling Point: 283.4°C at 760 mmHg
• Flash Point: 125.2°C
• Appearance: /
• Density: 1.115g/cm³
• Vapor Pressure: 0.00317mmHg at 25°C
• Refractive Index: 1.614
• PKA: 7.87±0.10(Predicted)
• CAS DataBase Reference: N2,N2-dimethylpyridine-2,5-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N2,N2-dimethylpyridine-2,5-diamine(4928-43-2)
• EPA Substance Registry System: N2,N2-dimethylpyridine-2,5-diamine(4928-43-2)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 4928-43-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N2,N2-dimethylpyridine-2,5-diamine is used as a synthetic intermediate for the production of various pharmaceutical compounds. Its strong nucleophilic property allows it to participate in a wide range of chemical reactions, making it a valuable component in the synthesis of drugs.
Used in Biochemistry Research:
N2,N2-dimethylpyridine-2,5-diamine is used as a reagent in biochemistry research. Its ability to donate electron pairs makes it a useful tool in studying the interactions between molecules and understanding the mechanisms of various biochemical processes.
Used in Organic Synthesis:
N2,N2-dimethylpyridine-2,5-diamine is used as a building block in the synthesis of complex organic compounds. Its versatile chemical properties enable it to be incorporated into a variety of molecular structures, contributing to the development of new materials and compounds with potential applications in various industries.

InChI:InChI=1/C7H11N3/c1-10(2)7-4-3-6(8)5-9-7/h3-5H,8H2,1-2H3

Upstream product

• 2554-75-8 N,N-dimethyl-5-nitropyridin-2-amine 
• 5683-33-0 2-(Dimethylamino)pyridine 
• 7647-01-0 hydrogenchloride 
• 4487-59-6 2-bromo-5-nitropyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 26163-07-5 5-bromo-2-dimethylaminopyridine 
• 1083329-54-7 5-N-benzylamino-2-N,N-dimethylaminopyridine 
• 124-40-3 dimethyl amine 

Downstream Products

• 1003938-52-0 N-[6-(dimethylamino)pyridin-3-yl]-5-fluoro-1-(3-fluorobenzyl)-1H-indole-2-carboxamide 
• 1435933-28-0 C₁₉H₂₅N₃O₂ 
• 1379032-15-1 5-(3-bromo-4-hydroxybenzylidene)-3-[6-(dimethylamino)pyridine-3-yl]-1,3-oxazolidin-2,4-dione 

Relevant articles and documents

COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS

The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.

As tyrosine kinase inhibitors of the nitrogen-containing heteroaromatic ring derivatives

The present invention relates to compounds as represented by general formula (I) as tyrosine kinase inhibitors, preparation method thereof, pharmaceutical compositions containing the compounds, and uses thereof for preventing and/or treating instances of B-cell related leukemia, inflammatory diseases and autoimmune diseases, wherein A, ring B, L1, L2, R1, R2, R3, a, b, c, d, e, p and q are as defined in the specification.

Discovery of potent transient receptor potential vanilloid 1 antagonists: Design and synthesis of phenoxyacetamide derivatives

We aimed to discover a novel type of transient receptor potential vanilloid 1 (TRPV1) antagonist because such antagonists are possible drug candidates for treating various disorders. We modified the structure of hit compound 7 (human TRPV1 IC50 = 411 nM) and converted its pyrrolidino group to a (hydroxyethyl)methylamino group, which substantially improved inhibitory activity (15d; human TRPV1 IC50 = 33 nM). In addition, 15d ameliorated bladder overactivity in rats in vivo.

Preparation of highly reactive pyridine- and pyrimidine-containing diarylamine antioxidants

We recently reported a preliminary account of our efforts to develop novel diarylamine radical-trapping antioxidants (Hanthorn, J. J. et al. J. Am. Chem. Soc. 2012, 134, 8306-8309) wherein we demonstrated that the incorporation of ring nitrogens into diphenylamines affords compounds which display a compromise between H-atom transfer reactivity to peroxyl radicals and stability to one-electron oxidation. Herein we provide the details of the synthetic efforts associated with that report, which have been substantially expanded to produce a library of substituted heterocyclic diarylamines that we have used to provide further insight into the structure-reactivity relationships of these compounds as antioxidants (see the accompanying paper, DOI: 10.1021/jo301012x). The diarylamines were prepared in short, modular sequences from 2-aminopyridine and 2-aminopyrimidine wherein aminations of intermediate pyri(mi)dyl bromides and then Pd-catalyzed cross-coupling reactions of the amines and precursor bromides were the key steps to yield the diarylamines. The cross-coupling reactions were found to proceed best with Pd(η3-1-PhC3H 4)(η5-C5H5) as precatalyst, which gave higher yields than the conventional Pd source, Pd2(dba) 3.

SUBSTITUTED DIARYLAMINES AND USE OF SAME AS ANTIOXIDANTS

The present invention relates to substituted heteroaromatic dianlamine compounds of Formula I and II, their pharmaceutically acceptable salts, and compositions thereof useful as antioxidants, wherein each of X, Y and Z are independently a carbon or nitrogen atom; R1 and R2 are each independently a hydrogen or an electron donating group, but are not both hydrogen, and wherein R1 and R2 are each bonded to a carbon atom in their own respective aryl ring.

PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Organic compounds

The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the formula (I): in which the substitutents are as defined in claim 1 and salts, solvates, hydrates and N-oxides thereof.

SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS

The invention pertains to heteroaromatic compounds of the formula I, as defined herein, that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the Formula (I): in which the substitutents are as defined in claim 1 and and salts, solvates, hydrates and N- oxides thereof.